HIV vaccine shows promise in human trial

  • HIV vaccine shows promise in human trial

HIV vaccine shows promise in human trial

"Although these data are promising, we need to remain cautious", said study leader Dan Barouch, a Harvard Medical School professor. In a similarly designed study, Barouch and colleagues tested the same vaccine for its ability to protect rhesus monkeys challenged with an HIV-like virus from infection. This vaccine is one of the five experimental HIV-1 vaccine concepts that reached such a success in nearly 40 years of HIV pandemic.

While there have been HIV vaccines that have been approved for human trials in the past, only one was shown to provide protection against the disease, and it's rate of protection was considered too low to be implemented more widely.

Jean-Daniel Lelievre of France's Vaccine Research Institute said the vaccine was likely not the "definitive" version, but may represent "a phenomenal advance". A new study published in the Lancet reveals that scientists have tested the vaccine on humans and rhesus monkeys, and they plan to administer it to a group of 2,600 women at risk for HIV in southern Africa next.

In the APPROACH trial of almost 400 participants, researchers conducted a multicenter, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and immunogenicity of several vaccine regimens in humans.

A vaccine against HIV has been a real challenge for scientists, because of this virus many strains. All the participants went through a random, double blind kind of trial which is being referred to as "mosaic" vaccine which is basically pieces of various HIV viruses, combined together to induce immune responses against the HIV strains.

About nine years ago, another HIV vaccine, RV144, also showed positive results in initial experiments carried out on 16,000 volunteers in Thailand.

Medical science has cured many diseases and now a new study reveals HIV vaccine that has the potential to protect people around the world as the treatment has shown promising results.

The APPROACH trial recruited 393 healthy, HIV-uninfected adults (aged 18-50 years) from 12 clinics in east Africa, South Africa, Thailand, and the US between February 2015 and October 2015.

"These results should be interpreted cautiously". However, creating a vaccine has proven very hard for scientists "because there are so many strains of the virus" and " because HIV is adept at mutating to elude attack from our immune systems".

To do this, they recruited 393 healthy, HIV-uninfected adults (aged 18 to 50 years) between February and October 2015. Over a 48-week period, they were given four vaccines. We do not have a licensed prophylactic, i.e., meant to prevent disease, HIV vaccine.

About 37 million people worldwide live with HIV or Aids, and there are an estimated 1.8 million new cases every year. All vaccine regimens were well-tolerated and induced robust immune responses in the participants.

"The road to the clinic is still unpredictable since the exact mode of action in humans is still unknown and the 67 percent protection in monkeys might not be replicable in humans", said George Williams Mbogo from the Burnet Institute in Australia, who wasn't involved in the study.